According to Zacks, “Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company’s product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid Therapeutics Inc. is based in New York, United States. “
A number of other analysts have also recently commented on the stock. ValuEngine cut shares of Ovid Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 1st. Cowen reiterated a “buy” rating on shares of Ovid Therapeutics in a research note on Monday, November 11th. Finally, William Blair reiterated a “buy” rating on shares of Ovid Therapeutics in a research note on Friday, November 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $13.13.
Hedge funds have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC acquired a new stake in Ovid Therapeutics in the 3rd quarter worth approximately $56,000. Alpine Global Management LLC acquired a new stake in Ovid Therapeutics in the 4th quarter worth approximately $69,000. Charles Schwab Investment Management Inc. acquired a new stake in Ovid Therapeutics during the 4th quarter valued at approximately $78,000. Tower Research Capital LLC TRC acquired a new stake in Ovid Therapeutics during the 4th quarter valued at approximately $79,000. Finally, Virtu Financial LLC acquired a new stake in Ovid Therapeutics during the 3rd quarter valued at approximately $80,000. Institutional investors own 17.34% of the company’s stock.
About Ovid Therapeutics
Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.